FDA approves Eucrisa for atopic dermatitis in infants
The FDA approved Pfizer’s supplemental new drug application for Eucrisa ointment, 2%, for children as young as age 3 months with mild-to-moderate atopic dermatitis, or AD.
Eucrisa (crisaborole) was previously approved for use in adults and children aged 2 years or older. The supplemental approval makes it the first and only steroid-free, topical prescription medication for patients with AD as young as 3 months of age, Pfizer said
No comments:
Post a Comment